Imprimis Pharmaceuticals (IMMY +12%) ramps higher today after the company says that had...

|About: Imprimis Pharmaceuticals, Inc. (IMMY)|By:, SA News Editor

Imprimis Pharmaceuticals (IMMY +12%) ramps higher today after the company says that had concluded its Type C meeting with the FDA, which included the review of the development plan for its lead phase 3 drug candidate, Impracor, a topical cream Non-Steroidal Anti-Inflammatory Drug.